Dana-Farber Cancer Institute

KEI Requests the NIH to Investigate Failure to Disclose Federal Funding in Opdivo and Keytruda Patents

Posted on by Claire Cassedy

On December 20, 2019, Knowledge Ecology International (KEI) filed a request to the National Institutes of Health (NIH) that it investigate an apparent failure to disclose federal funding in patents associated with cancer immunotherapies Opdivo and Keytruda. A court case… Continue Reading →

James Griffin, Dana-Farber Cancer Institute and Novartis failure to disclose NIH funding for patents on leukemia drug midostaurin (Trade name Rydapt)

Posted on by James Love

On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading →